Simris Group ABOMXSTO: SIMRIS_B

SIMRIS_B: EBITDA loss narrowed 51% in Q2, but liquidity remains a critical concern

· Issued by Simris Group AB

Q2 2025 saw improved EBITDA and EBIT losses, but interim revenue declined 27% year-over-year. Cash reserves are low, with urgent funding needs, while the company advances preclinical oncology programs and winds down legacy operations.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Simris Group AB on 6ix

Story so far

Earlier from Simris

Later from Simris

All Simris news releases